



This list of clinical research protocols relating to pancreatic cancer is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER.

A searchable PDQ Web site is also accessible at <http://cancernet.nci.nih.gov/trialsrch.shtml>

CLINICAL RESEARCH PROTOCOLS FOR PANCREATIC CANCER

Diagnostic

LAC-USC-3P941A, NCI-V97-1339 Phase II Diagnostic Study of Laparoscopy With Laparoscopic Ultrasound in Pancreatic Cancer

Chairperson: Dilip Parekh. Telephone: 213-342-5837. Lead organization: USC/Norris Comprehensive Cancer Center. Age range: Over 18.

Supportive Care

NU-98CC2, NCI-G00-1703 Phase I/II Pilot Study of Enteral Wall-stents in Patients With Duodenal Obstruction Secondary to Malignancy

Chairperson: Willis Parsons, III. Telephone: 312-695-4028. Lead organization: Robert H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: 18 and over.

NU-97X1, NCI-G00-1685 Phase II Study of Octreotide as Palliative Therapy for Inoperable Bowel Obstruction Secondary to Cancer

Chairperson: J. Cameron Muir. Telephone: 312-908-5250. Lead organization: Robert H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: Over 18.

CPMC-IRB-8544, NCI-V99-1538 Phase III Study of Gemcitabine Versus Intensive Pancreatic Proteolytic Enzyme Therapy With Ancillary Nutritional Support in Patients With Stage II, III, or IV Adenocarcinoma of the Pancreas

Chairperson: John Chabot. Telephone: 212-305-9468. Lead organization: Herbert Irving Com-

prehensive Cancer Center. Age range: 18 to physiologic 65.

Phase I

NCCTG-964352 Phase I Study of Gemcitabine, Cisplatin, and Radiation Therapy in Patients With Unresectable or Locally Recurrent Pancreatic and Gastric Cancer

Chairperson: James A. Martenson, Jr. Telephone: 507-284-4561. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

PCI-97-108, NCI-T97-0109 Phase I Study of the Radiosensitizer Gadolinium Tetroxide With Concurrent Radiotherapy in Patients With Advanced Biliary Tree or Pancreatic Cancer

Chairperson: Ramesh Ramnathan. Telephone: 412-648-6507. Lead organization: University of Pittsburgh Cancer Institute. Age range: 18 and over.

MSKCC-98019, NCI-H98-0020 Phase I Study of Gemcitabine in Combination With Radiation Therapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

Chairperson: David Paul Kelsen. Telephone: 212-639-2933. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

Phase I/II

NYU-9703, NCI-G98-1423 Phase I/II Study of Gemcitabine and Cisplatin Followed by Combined

Chemoradiation and/or Surgical Resection in Patients With Locally Advanced Pancreatic Cancer

Chairperson: Howard S. Hochster. Telephone: 212-652-1912. Lead organization: Kaplan Cancer Center. Age range: 18 and over.

NCCTG-984351 Phase I/II Study of Gemcitabine Plus Oxaliplatin in Patients With Refractory Locally Advanced or Metastatic Pancreatic Carcinoma

Chairperson: Steven R. Alberts. Telephone: 507-284-4918. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

CMMI-C-033-98, NCI-H99-0042, NCI-V99-1571 Phase I/II Study of High Dose Radioimmunotherapy With Yttrium Y 90 Anti-CEA Monoclonal Antibody MN-14 Plus Autologous Peripheral Blood Stem Cell Rescue in Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer

Chairperson: Malik Juweid. Telephone: 973-844-7115. Lead organization: Garden State Cancer Center. Age range: 18 and over.

Phase II

EORTC-40984 Phase II Randomized Study of Docetaxel and Gemcitabine Versus Docetaxel and Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma

Chairperson: Manfred Lutz. Telephone: 0049-731-502-01 (Germany). Lead organization: EORTC Gastrointestinal Tract Cancer Group. Age range: 18 and over.

EORTC-16994P, ASTA-D-19575-3166 Phase II Randomized Study of Glufosfamide With or Without Hydration in Patients With Advanced Pancreatic Cancer

Chairperson: Nicholas A. Pavlidis. Telephone: 30-651-99394 (Greece). Lead organization: EORTC Early Clinical Studies Group. Age range: 18 and over.

SVMC-ONC-222P, NCI-V96-0886 Phase II Study of Active Intra-lymphatic Immunotherapy With IFN-A-Treated Allogeneic Tumor Cells Plus GM-CSF and CTX for Advanced Pancreatic Adenocarcinoma

Chairperson: Charles Wiseman. Telephone: 213-484-7575. Lead organization: St. Vincent Medical Center - Los Angeles. Age range: 18 and over.

BRI-PA-2 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Adenocarcinoma of the Pancreas

Chairperson: Stanislaw R. Burzynski. Telephone: 713-335-5697. Lead organization: Burzynski Research Institute. Age range: 18 and over.

DUMC-97093, NCI-G98-1457 Phase II Study of Carcinoembryonic Antigen (CEA) Peptide Pulsed Dendritic Cells in Patients With Resected Stage I, II, and III Adenocarcinoma of the Pancreas Expressing CEA

Chairperson: Michael A. Morse. Telephone: 919-681-3480. Lead organization: Duke Comprehensive Cancer Center. Age range: 18 and over.

MDA-DM-98071, NCI-T98-

0028 Phase II Study of Dolastatin 10 in Patients With Metastatic Pancreatic Adenocarcinoma

Chairperson: Robert A. Wolff. Telephone: 713-792-2828. Lead organization: University of Texas - MD Anderson Cancer Center. Age range: 18 and over.

SWOG-9700 Phase II Study of Fluorouracil, Leucovorin, Mitomycin and Dipyridamole in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma

Chairperson: William H. Isacoff. Telephone: 310-824-4133. Lead organization: Southwest Oncology Group. Age range: not specified.

BRUOG-PA-77, NCI-T98-0067 Phase II Study of Gemcitabine and Trastuzumab (Herceptin) in Patients With Metastatic Pancreatic Cancer and Overexpression of HER2-Neu

Chairperson: Howard Safran. Telephone: 401-793-7151. Lead organization: Brown University Oncology Group. Age range: Over 18.

WSU-D-1993, NCI-G99-1553, WSU-04-03-99-M01-FB Phase II Study of Gemcitabine, Cisplatin, and Fluorouracil in Patients With Unresectable Stage III or IV Pancreatic Adenocarcinoma

Chairperson: Philip A. Philip. Telephone: 313-745-9155. Lead organization: Barbara Ann Karmanos Cancer Institute. Age range: Adult.

CMM-95079, NCI-V95-0760, CH/UMC-95079 Phase II Study of Interstitial Colloidal Phosphorus

P32 Integrated into the Treatment of Patients With Unresectable Pancreatic Cancer

Chairperson: Stanley E. Order. Telephone: 516-222-2727. Lead organization: Center for Molecular Medicine. Age range: 18 and over.

UAB-9915, NCI-G00-1730, ISIS-2503-CS5, UAB-F990526011 Phase II Study of ISIS 2503 in Patients With Advanced Adenocarcinoma of the Pancreas

Chairperson: James Posey, III. Telephone: 205-934-0916. Lead organization: University of Alabama Comprehensive Cancer Center. Age range: 18 and over.

IUMC-9710-07, NCI-T98-0046 Phase II Study of Perillyl Alcohol in Patients With Resectable, Stage II or Stage III Pancreatic Adenocarcinoma

Chairperson: Patrick J. Loehrer, Sr. Telephone: 317-278-7418. Lead organization: Indiana University Cancer Center. Age range: 18 and over.

SWOG-S9924 Phase II Study of R115777 in Patients With Advanced Adenocarcinoma of the Pancreas

Chairperson: Charles A. Coltman, Jr. Telephone: 210-616-5580. Lead organization: Southwest Oncology Group. Age range: Not specified.

FCCC-00005, NCI-45 Phase II Study of R115777 in Patients With Metastatic Pancreatic Cancer

Chairperson: Neal Jay Meropol. Telephone: 215-728-2450. Lead organization: Fox Chase Cancer Center. Age range: 18 and over.

Phase II/III

PD-994-011, ILEX-994-011 Randomized, Double Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion in the Treatment of Patients With Advanced Pancreatic Cancer

Chairperson: Kathy M. Diener. Telephone: 734-622-1985. Lead organization: Parke-Davis Pharmaceutical Research. Age range: 18 and over.

Phase III

EORTC-05962 Phase III Randomized Multicenter Trial of Infusional Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally Advanced or Metastatic Pancreatic Cancer

Chairperson: Francis Levi. Telephone: 33-1-45-59-35-14 (France). Lead organization: EORTC Chronotherapy Study Group. Age range: 18 to 75.

JRF-R115777-INT-11 Phase III Randomized Study of Gemcitabine With or Without R115777 in Patients With Advanced Pancreatic Cancer

Contact: Patient Referral Janssen Research Foundation. Telephone: 888-773-9831. Lead organization: Janssen Research Foundation. Age range: 18 and over.

SUPERGEN-RFS2000-06, PCI-99-001 Phase III Randomized Study of Nitrocamptothecin Versus Fluorouracil in Patients With Recurrent or Refractory Pancreatic Cancer

Chairperson: Rande Rolens. Telephone: 925-327-0200. Lead organization: SuperGen, Inc. Age range: Over 18.

SUPERGEN-RFS2000-02 Phase III Randomized Study of Oral Nitrocamptothecin vs Gemcitabine in Chemotherapy Naive Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Pancreas

Chairperson: Rande Rolens. Telephone: 925-327-0200. Lead organization: SuperGen, Inc. Age range: Over 18.

SUPERGEN-RFS2000-09 Phase III Randomized Study of Oral Nitrocamptothecin vs Most Appropriate Chemotherapy in Patients With Recurrent or Refractory Adenocarcinoma of the Pancreas

Chairperson: Rande Rolens. Telephone: 925-327-0200. Lead organization: SuperGen, Inc. Age range: Over 18.

MAYO-974301, NCI-G97-1302 Phase III Randomized Study of Pancreatoduodenectomy With or Without Extended Lymphadenectomy Followed by Chemoradiation Therapy for Resectable Pancreatic Adenocarcinoma

Chairperson: Richard M. Goldberg. Telephone: 507-266-0029. Lead organization: Mayo Clinic Cancer Center. Age range: 18 and over.

RTOG-9704 Phase III Study of Adjuvant Fluorouracil Chemoradiation Preceded and Followed by Fluorouracil or Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma

Chairperson: William F. Regine.
 Telephone: 606-323-6486. Lead organization: Radiation Therapy Oncology Group. Age range: 18 and over.

Legend for Abbreviations:

- | | | | | | |
|---------|---|---|----------|---|--|
| ASTA | = | ASTA Medica | NCCTG | = | North Central Cancer Treatment Group |
| BRI | = | Burzynski Research Institute | NU | = | Robert H. Lurie Comprehensive Cancer Center, Northwestern University |
| BRUOG | = | Brown University Oncology Group | NYU | = | New York University Cancer Center |
| CMMI | = | Center for Molecular Medicine and Immunology | PCI | = | University of Pittsburgh Cancer Institute |
| CPMC | = | Columbia Presbyterian Medical Center | PD | = | Parke-Davis Pharmaceutical Research |
| DUMC | = | Duke Comprehensive Cancer Center | RTOG | = | Radiation Therapy Oncology Group |
| EORTC | = | European Organization for Research on Treatment of Cancer | SUPERGEN | = | SuperGen, Inc |
| FCCC | = | Fox Chase Cancer Center | SVMC | = | St. Vincent Medical Center |
| ILEX | = | ILEX Oncology, Inc | SWOG | = | Southwest Oncology Group |
| IUMC | = | Indiana University Medical Center | UAB | = | University of Alabama Comprehensive Cancer Center |
| JRF | = | Janssen Research Foundation | WSU | = | Wayne State University |
| LAC-USC | = | University of Southern California | | | |
| MAYO | = | Mayo Clinic Cancer Center | | | |
| MDA | = | M.D. Anderson Cancer Center | | | |
| MSKCC | = | Memorial Sloan-Kettering Cancer Center | | | |